Patents by Inventor Abhay RATHORE

Abhay RATHORE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of serotonergic drugs to treat virus-induced thrombocytopenia
    Patent number: 11426408
    Abstract: The present invention relates to the use of serotonergic compounds for the treatment of virus-induced thrombocytopenia. More particularly, the invention relates to methods of treating thrombocytopenia by blocking serotonin activity. For example, inhibitors of receptor 5HT2A and/or receptor 5HT1A and/or inhibitors of mast cell degranulation and/or inhibitors of serotonin uptake may be used. Preferably, the thrombocytopenia is induced by dengue or Japanese Encephalitis virus, and the inhibitors are preferably ketanserin, WAY-100135, sarpogrelate, or fluoxetine.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 30, 2022
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Ashley Lauren St. John, Mohamad Fadhli Bin Masri, Abhay Rathore
  • Dosing regimens of celgosivir for the treatment of dengue
    Patent number: 11219616
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: January 11, 2022
    Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • USE OF SEROTONERGIC DRUGS TO TREAT VIRUS-INDUCED THROMBOCYTOPENIA
    Publication number: 20200352947
    Abstract: The present invention relates to the use of serotonergic compounds for the treatment of virus-induced thrombocytopenia. More particularly, the invention relates to methods of treating thrombocytopenia by blocking serotonin activity. For example, inhibitors of receptor 5HT2A and/or receptor 5HT1A and/or inhibitors of mast cell degranulation and/or inhibitors of serotonin uptake may be used. Preferably, the thrombocytopenia is induced by dengue or Japanese Encephalitis virus, and the inhibitors are preferably ketanserin, WAY-100135, sarpogrelate, or fluoxetine.
    Type: Application
    Filed: October 31, 2018
    Publication date: November 12, 2020
    Inventors: Ashley Lauren ST. JOHN, Mohamad Fadhli Bin MASRI, Abhay RATHORE
  • Novel Dosing Regimens of Celgosivir for the Treatment of Dengue
    Publication number: 20200338050
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Application
    Filed: December 23, 2019
    Publication date: October 29, 2020
    Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • Dosing regiments of celgosivir for the treatment of dengue
    Patent number: 10517854
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: December 31, 2019
    Assignees: 60 Degrees Pharmaceuticals LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • Novel Dosing Regimens of Celgosivir for the Treatment of Dengue
    Publication number: 20180064693
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.
    Type: Application
    Filed: September 18, 2017
    Publication date: March 8, 2018
    Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong OOI, Jenny Low
  • Dosing regimens of celgosivir for the treatment of dengue
    Patent number: 9763921
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 19, 2017
    Assignees: 60 Degrees Pharmaceuticals LLC, Singapore Health Services PTE LTD, National University Of Singapore
    Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
  • Novel Dosing Regimens of Celgosivir for the Treatment of Dengue
    Publication number: 20160030403
    Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.
    Inventors: Geoffrey S. DOW, Subhash VASUDEVAN, Mark REID, Glynn MORRISH, Cynthia SUNG, Abhay RATHORE, Satoru WATANABE, Eng Eong OOI, Jenny LOW